A Higher Score on the Dermatology Life Quality Index, Being on Systemic Treatment and Having a Diagnosis of Psoriatic Arthritis is Associated with Increased Costs in Patients with Plaque Psoriasis
| Autor: | Berndt Stenberg, Lotus Mallbris, Susanne Qvitzau, Mats Ekelund |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Cost-Benefit Analysis Health Status costs macromolecular substances Dermatology Severity of Illness Index Drug Costs Psoriatic arthritis Cost of Illness Disease severity Predictive Value of Tests Surveys and Questionnaires Absenteeism Humans Medicine Dermatologi och venereologi In patient DLQI skin and connective tissue diseases Aged Retrospective Studies Sweden Plaque psoriasis business.industry Arthritis Psoriatic Health Care Costs psoriasis General Medicine Dermatology Life Quality Index Middle Aged medicine.disease humanities Dermatology and Venereal Diseases Treatment Outcome cost-of-illness Quality of Life Health Resources Female Sick Leave business |
| Zdroj: | Acta Dermato Venereologica. 93:684-688 |
| ISSN: | 0001-5555 |
| DOI: | 10.2340/00015555-1591 |
| Popis: | The aim of this study was to examine the relationship between measures of disease severity and costs from a socie-tal perspective in patients with plaque psoriasis. Dermatologists in Sweden recruited 443 consecutive patients who had had no biological treatment during the past 12 months. Following a Psoriasis Area and Severity Index (PASI) assessment, subjects completed self-assessments on health status/quality of life and a healthcare resource utilization/work status questionnaire. The costs of healthcare resources and sick-leave due to plaque psoriasis were estimated and related to the subject's health status. A patient's Dermatology Life Quality Index (DLQI) and being on systemic therapy, or having diagnosis of psoriatic arthritis, appeared to be more strongly associated with direct and indirect costs than did their PASI. The cost of biological therapy should be considered from the perspective of the already high costs of patients with high DLQI undergoing traditional systemic treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|